Pacira Pharma (PCRX) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021
August 3, 2021 8:00 AM EDT-- EXPAREL average daily sales at 178% of the prior year second quarter ---- Conference call today at 8:30 a.m. ET --
PARSIPPANY, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2021.
Second Quarter 2021 Financial Highlights
Total revenues of $135.6 millionGAAP net income of $19.1... More